Sabin-IPV is an inactivated poliovirus vaccine
derived from attenuated strains, and its safety and efficacy are expected to be comparable to the inactivated polio vaccines derived from virulent strains, which are commonly used outside Japan.
(10.) Introduction of inactivated poliovirus vaccine
into oral poliovirus vaccine-using countries.
MMR, inactivated poliovirus vaccine
, and varicella vaccine are administered SQ.
Starting in 2015, injectable trivalent inactivated poliovirus vaccine
(IPV) was introduced into routine immunization schedules in OPV-using countries, generally at 14 weeks of age.
The progress of our dengue program, along with other recent achievements, such as Phase 2b field trial initiation for our norovirus vaccine candidate and our partnership with the Bill & Melinda Gates Foundation to develop a Sabin-strain inactivated poliovirus vaccine
(sIPV) exemplify how we are researching, developing and providing vaccines to protect populations in need, wherever they may reside.
The children also received all other childhood recommended vaccines (DTaP, hepatitis B vaccine, inactivated poliovirus vaccine
, Haemophilus influenzae type b vaccine, and meningococcal group C conjugate vaccine).
In this single-blind, Phase II study, 609 infants were randomized 1:1 to receive either Hib-MenCY-TT or licensed Hib vaccine at 2, 4, and 6 months concomitantly with DTaP-Hep B-IPV (Pediarix[R] Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B [Recombinant] and Inactivated Poliovirus Vaccine
Combined) and pneumococcal 7-valent conjugate vaccine (Prevnar[R] Pneumococcal 7-valent Conjugate Vaccine Diphtheria CRM Protein).
VAPP denotes vaccine-associated paralytic poliomyelitis; DTaP-HIB, diptheria tetanus acellular pertussis-Haemophilus influenzae type B vaccine; IPV, inactivated poliovirus vaccine
Vaccination options for these activities include the use of monovalent oral poliovirus vaccine type 2 (mOPV2) and/or inactivated poliovirus vaccine
(IPV) for polio vaccination campaigns.
With this funding, Takeda will develop, license and supply at least 50 million doses per year of Sabin-strain inactivated poliovirus vaccine
(sIPV) to more than 70 developing countries.
6 Two poliovirus vaccines are currently licensed in the U.S.: inactivated poliovirus vaccine
(IPV) and oral poliovirus (OPV).
To minimize the risks for paralytic poliomyelitis associated with PV2, vaccination with the inactivated poliovirus vaccine
(IPV) will be needed for the foreseeable future (6).